| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic/Nuclear Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California
Correspondence: For correspondence or reprints contact: Johannes Czernin, MD, Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic/Nuclear Medicine, David Geffen School of Medicine, UCLA, 10833 Le Conte Ave., Los Angeles, CA 90095-6948. E-mail: jczernin{at}mednet.ucla.edu
PET/CT with 18F-FDG is increasingly being used for staging, restaging, and treatment monitoring for cancer patients. CT is still frequently used only for attenuation correction and lesion localization. However, increasing sales of high-end scanners that combine PET with 64-detector CT strongly suggest that the field is moving toward a comprehensive concept, whereby diagnostic CT studies during intravenous contrast material application are combined with the highest-quality PET studies. At many institutions, in-line PET/CT has replaced separately acquired PET and CT examinations for many oncologic indications. This replacement has occurred despite the fact that only a relatively small number of well-designed prospective studies have verified imaging findings against the gold standard of histopathologic tissue evaluation. However, a large number of studies have used acceptable reference standards, such as pathology, imaging, and other clinical follow-up findings, for validating PET/CT findings. From these data, we believe, has emerged reliable evidence in support of the notion that PET/CT offers diagnostic advantages over its individual components for the major cancers.
Key Words: cancer • staging • PET/CT
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
This article has been cited by other articles:
|
|
 |
|
  M. Weiler-Sagie, O. Bushelev, R. Epelbaum, E. J. Dann, N. Haim, I. Avivi, A. Ben-Barak, Y. Ben-Arie, R. Bar-Shalom, and O. Israel 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients J. Nucl. Med., January 1, 2010; 51(1): 25 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Y. Lee and K. C. P. Li Systems Diagnostics: The Systems Approach to Molecular Imaging Am. J. Roentgenol., August 1, 2009; 193(2): 287 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Hausner, C. K. Abbey, R. J. Bold, M. K. Gagnon, J. Marik, J. F. Marshall, C. E. Stanecki, and J. L. Sutcliffe Targeted In vivo Imaging of Integrin {alpha}v{beta}6 with an Improved Radiotracer and Its Relevance in a Pancreatic Tumor Model Cancer Res., July 15, 2009; 69(14): 5843 - 5850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Bolus, R. George, J. Washington, and B. R. Newcomer PET/MRI: The Blended-Modality Choice of the Future? J. Nucl. Med. Technol., June 1, 2009; 37(2): 63 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck, S. G. Nekolla, S. I. Ziegler, and A. Drzezga Reply: SPECT/CT J. Nucl. Med., June 1, 2009; 50(6): 1009 - 1010. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Hicks Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 31S - 42S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Allen-Auerbach and W. A. Weber Measuring Response with FDG-PET: Methodological Aspects Oncologist, April 1, 2009; 14(4): 369 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Heusner, S. Kuemmel, L. Umutlu, A. Koeninger, L. S. Freudenberg, E. A.M. Hauth, K. R. Kimmig, M. Forsting, A. Bockisch, and G. Antoch Breast Cancer Staging in a Single Session: Whole-Body PET/CT Mammography J. Nucl. Med., August 1, 2008; 49(8): 1215 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck, S. Nekolla, S. Ziegler, A. Beer, B. J. Krause, K. Herrmann, K. Scheidhauer, H.-J. Wester, E. J. Rummeny, M. Schwaiger, et al. SPECT/CT J. Nucl. Med., August 1, 2008; 49(8): 1305 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Townsend Dual-Modality Imaging: Combining Anatomy and Function J. Nucl. Med., June 1, 2008; 49(6): 938 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. van Meerbeeck, S. Meersschout, R. De Pauw, I. Madani, and W. De Neve Modern Radiotherapy as Part of Combined Modality Treatment in Locally Advanced Non-Small Cell Lung Cancer: Present Status and Future Prospects Oncologist, June 1, 2008; 13(6): 700 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Federman and S. A. Feig PET/CT in Evaluating Pediatric Malignancies: A Clinician's Perspective J. Nucl. Med., December 1, 2007; 48(12): 1920 - 1922. [Full Text] [PDF]
|
|
|
|
|
|
J. Czernin and H. R. Schelbert Introduction J. Nucl. Med., January 1, 2007; 48(1_suppl): 2S - 3S. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
